🇫🇷 Neovacs S.A.
ALNEV.PAFundamentals
Gross Margin
11.6%
Op. Margin
-
Net Margin
-
ROIC
-23.3%
Rev Growth
-55.8%
Valuation
Price
0.37 EUR
Day
+0.00%
52-Week Range
0 - 5,890
Market Cap
0M EUR
Fwd P/E
3.7x
EV/EBITDA
-
Div Yield
-
Annual income statement #
Neovacs S.A. annual revenue, operating income and net income in EUR, 2016 to 2025. Revenue was 161,780 in 2025.
| Year | Revenue (EUR) | Operating income | Net income | Net margin |
|---|---|---|---|---|
| 2025 | 161,780 | -5.4m | -4.9m | |
| 2024 | 366,346 | -6.8m | -32.9m | |
| 2023 | 533,412 | -6.9m | -8.7m | |
| 2022 | 1,112 | -6.4m | -3.5m | |
| 2021 | 22,595 | -7.8m | -11.8m | |
| 2020 | 29,784 | -3.5m | -6.1m | |
| 2019 | 95,154 | -8.3m | -7.5m | |
| 2018 | 145,000 | -13.1m | -10.8m | |
| 2017 | 12,834 | -19.1m | -14.8m | |
| 2016 | 15,427 | -17.2m | -13.9m |
Financial Data #
Segment Breakdown #
Peers #
OXUR.BR MAGLE.ST 2CUREX.ST PTP.DE NANECH.ST ALINT.PA STABL.ST BIOS.BR ATORX.ST GUARD.ST ·
Compare in Screener
Dividends
Bubble
Events #
| Date | Type | Details | Price | Amount |
|---|